Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.28−0.17 (-0.83%)
Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%
Viatris operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Viatris's operating income for the twelve months ending Jun 30, 2026 was -$87.30M. For fiscal 2025 it was -$2.66B, down 26467.3% from the year before. The highest annual figure on record is $1.61B in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.66B | -26467.3% |
| FY2024 | Dec 31, 2024 | $10.10M | -98.7% |
| FY2023 | Dec 31, 2023 | $766.20M | -52.6% |
| FY2022 | Dec 31, 2022 | $1.61B | – |
| FY2021 | Dec 31, 2021 | -$34.00M | – |
| FY2020 | Dec 31, 2020 | -$210.80M | -129.5% |
| FY2019 | Dec 31, 2019 | $715.50M | -21.0% |
| FY2018 | Dec 31, 2018 | $905.60M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.30M | -97.3% |
| Q1 FY2026 | Mar 31, 2026 | -$79.70M | – |
| Q4 FY2025 | Dec 31, 2025 | -$192.70M | – |
| Q3 FY2025 | Sep 30, 2025 | $178.80M | -20.8% |
| Q2 FY2025 | Jun 30, 2025 | $233.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.88B | -1513.5% |
| Q4 FY2024 | Dec 31, 2024 | -$179.80M | – |
| Q3 FY2024 | Sep 30, 2024 | $225.90M | -50.0% |
| Q2 FY2024 | Jun 30, 2024 | -$239.90M | -165.0% |
| Q1 FY2024 | Mar 31, 2024 | $203.90M | -49.0% |
| Q4 FY2023 | Dec 31, 2023 | -$454.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $451.70M | -19.4% |
| Q2 FY2023 | Jun 30, 2023 | $369.20M | -32.7% |
| Q1 FY2023 | Mar 31, 2023 | $399.80M | -43.5% |
| Q4 FY2022 | Dec 31, 2022 | -$201.30M | – |
| Q3 FY2022 | Sep 30, 2022 | $560.10M | +56.6% |
| Q2 FY2022 | Jun 30, 2022 | $548.70M | – |
| Q1 FY2022 | Mar 31, 2022 | $707.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$77.60M | – |
| Q3 FY2021 | Sep 30, 2021 | $357.60M | +1.8% |
| Q2 FY2021 | Jun 30, 2021 | -$47.80M | -135.6% |
| Q1 FY2021 | Mar 31, 2021 | -$266.20M | -244.1% |
| Q4 FY2020 | Dec 31, 2020 | -$881.10M | – |
| Q3 FY2020 | Sep 30, 2020 | $351.40M | – |
| Q2 FY2020 | Jun 30, 2020 | $134.20M | – |
| Q1 FY2020 | Mar 31, 2020 | $184.70M | – |
See a number that looks wrong?